Preparedness of the CTSA's Structural and Scientific Assets to Support the Mission of the National Center for Advancing Translational Sciences (NCATS) by Bernard, Gordon R. et al.
 Introduction 
 On December 23, 2011, President Obama signed the Consolidated 
Appropriations Act, 2012 1 that included the establishment of a 
new National Institutes of Health center, the National Center 
for Advancing Translational Sciences (NCATS), with a budget 
of $576.5 million. 2 Th e new center will speed movement of 
discoveries from lab to patients and identify and overcome hurdles 
that slow the development of eff ective treatments and cures. 3 Th ese 
are not new goals; however, the bold move to form a new center, to 
dissolve another and to reorganize its various components to drive 
synergies is a rare, if not unprecedented, occurrence. Already, it 
is causing government offi  cials, scientists, and the lay public to 
pay attention. Th e largest single component of the new center will 
be the extant Clinical and Translational Science Award (CTSA) 
program, housed within the Division of Clinical Innovation and 
funded at approximately $487.8 million. 4 Each individual CTSA 
has been developing infrastructure for the very transformation 
that NCATS will propel. Th e fi rst 5 years of the CTSA consortium 
can be characterized as an emergent, reengineering process, during 
which institutions ramped up their capabilities and research 
organizations were incrementally added to achieve critical 
mass (now 60 sites, see the Appendix). Th e consortium—what 
could be called “version 1.0”—was developed within a strategic 
framework wherein the broadest constituencies of translational 
sciences were empowered and engaged. A signifi cant achievement 
has been the establishment and strengthening of the internal 
connections within this network—between individual scientists, 
across disciplines, and among academic organizations. As a 
consortium, we are now positioned to produce transformational 
change in translational sciences within the evolving NCATS, in 
what could be called “CTSA 2.0.” In this commentary, we describe 
the pertinent ways in which CTSAs are structured and briefl y 
defi ne a path to support the NCATS’s mission and the common 
vision of improved societal health. 
 The Organization and Emphasis of CTSAs 
 A full spectrum of translational science 
 Basic science discoveries feed the pipeline for translational and 
clinical research that seeks to move discoveries into practice and 
policy to improve health. Establishing the effi  cacy of a new drug, 
biologic, device, diagnostic, or preventative intervention through 
clinical research in controlled experimental settings creates 
preliminary evidence for application to clinical practice. Although 
the establishment of safety and effi  cacy is requisite to availability 
of new therapies, proof of real-world safety, and eff ectiveness is 
equally vital to actually aff ect health. We believe that CTSAs must 
support all of these stages if we are to systematically improve health; 
therefore, CTSAs, in the aggregate, cover the entire spectrum 
of translational science. Importantly, the process by which 
translational science occurs requires an institutional framework 
entailing familiarity with all stages, and as such, the “science of 
translation” has become a fundamental focus and principle of 
the CTSAs. Wisely, in authorizing NCATS, Congress encouraged 
the new Center “study steps in the therapeutics development 
and implementation process…to identify bottlenecks…that are 
amenable to re-engineering, and develop new technologies and 
innovative methods for streamlining the process.” 5 Th e large 
number of clinical and translational (C&T) studies supported 
or conducted under the auspices of the CTSA programs provides 
a platform for process analyses that, working with operations 
experts, address this defi ciency and holds promise for ways to 
reengineer processes. 6 
 A disease-agnostic approach to providing infrastructure 
 As scientists we can understand the notion that infrastructure 
is not always the most alluring topic. But as CTSA Principal 
Investigators and institutional leaders, we have begun to see the 
immense importance in the creation of a resource/program/
service that: (1) works across disease areas, (2) does not have 
to be recreated, and (3) fuels scientifi c innovation by its very 
existence. Th e nature of our operations in creating broad, reusable 
infrastructure is one of the most prominent symbols of what 
we do. Th ere is a proxy for measuring the extent to which we 
perform well: grant funding obtained from NIH’s categorical 
institutes and centers (I/Cs). CTSA support systems (some 
described here) positively impacts the diverse research funded 
by the NIH Institutes, Centers, and Offi  ces. Indeed, in the most 
recently reported project period, the CTSA program supported 
the research activities of 5,886 unique NIH grants ( Figure 1 ). 
Moreover, the support provided oft en reduces costs for the services 
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off ered, extending the purchase power of the NIH funding. CTSA 
support is supplemented by considerable institutional matching. 
Th at Deans and CEOs are willing to co-invest (substantially, in 
most cases) in this infrastructure is yet additional evidence of the 
perceived benefi ts of the CTSA model. 
 Supporting investigators in early-stage, hypothesis-driven 
pilot studies 
 Allocation of pilot funds is an imperative function of the CTSAs 
to jumpstart innovative science. All sites support pilot and 
collaborative studies that allow clinical and translational trainees 
or researchers to generate preliminary data for submission of 
grant applications, and/or are intended to develop innovative 
methods and technologies and new collaborations. Local CTSA 
pilot support of health-related research provides for rapid funding 
that is typically not available through other sources and is essential 
to investigators who need to generate preliminary data. Th ese 
programs are designed to be fl exible and responsive to changing 
opportunities in the fi eld by providing unique resources and 
fostering new investigative talent in diff erent disease domains. 
CTSA sites follow accepted standards of rigorous scientifi c review. 
Scientifi c review of the proposed health-related research is handled 
by faculty who are knowledgeable in the various disciplines and 
methodologies related to the scientifi c areas of the applicants. 
Th is distributed model for funding pilot studies using CTSA and 
matching institutional support provides small-scale and early-stage 
funding. Approximately, 2,000 pilot studies were conducted across 
CTSAs in the last reporting year ( Figure 2 ), greatly enhancing the 
resultant quality of preliminary data and simultaneously derisking 
subsequent submissions to NIH and other federal funding agencies. 
It also represents a fl exible infrastructure for locally off ered RFAs 
that can refl ect NIH priorities. 
 Regulatory support 
 Th e CTSA consortium has served an active role in not only 
providing research-focused support for regulatory compliance 
and management, but in greatly streamlining processes at the 
institutional level. Spurred by nationwide comparative studies 
of protocol processing times, many CTSA sites have measurably 
reduced the length of time for Institutional Review Board protocol 
review and approval, as well as contract negotiations and fi nal 
agreements. Development of IRB consortia has emerged, providing 
multiple-site, single IRB research networks. Many CTSA sites are 
also implementing an Offi  ce for Human Research Protections-
approved, collaborative IRB review model supported by an 
electronic sharing resource. Also, consistent with the NCATS 
mission of advancing the underpinning methods of translational 
science, CTSAs are contributing novel approaches to clinical trial 
 Figure 1.  Federal grants that benefi ted from the CTSA grant resources for investigators whose research was aided by the resources of the CTSA (as reported in site specifi c 
annual progress reports, 2010). 
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design (such as N-of-1 and innovative adaptive designs), conduct, 
and analysis that interface with the regulatory requirements in 
ways that will enhance translation of new treatments into use. 
In addition, every CTSA provides research participant advocacy 
functions which work with investigators, trainees, and research 
teams to promote and facilitate the safe and ethical conduct of 
human research. 
 Participant recruitment 
 Recruitment and retention has become a predominant concern 
due to recognition that failure to enroll any subject is not rare 
in clinical studies, and failure to recruit the target number of 
subjects is common. 7 As one example of a tool to help in recruiting 
volunteers, the CTSA-supported ResearchMatch is a disease-
neutral, institution-neutral, Web-based research matching 
service. Without signifi cant publicity and no advertising, 20,000 
registrants have volunteered (and simultaneously learned more 
about how they can help advance science as participants) and 
ResearchMatch already serves  approximately 1,000 researchers 
 regardless of disease focus . 8 CTSAs are also starting to use an i2b2 or 
other electronic medical record (EMR)-based systems to establish 
protocol cohort development at given sites to document the 
adequacy of patient populations (e.g., rapidly quantify numbers 
of subjects with specifi c diseases). At several CTSA sites, these and 
other strategies have resulted in an increase from 60% to 125% 
in the target subject accrual rate for clinical trials. 9 
 Sustaining the Enterprise: Educating and Training Scien-
tists in C&T Research 
 Th e CTSAs are ensuring that our nation will have a full pipeline 
of investigators who have the comprehensive skills needed to 
continue to bring novel therapies, diagnostics, and preventives 
to the public, and are able to work across the translational 
research continuum. Th e program supports multiple educational 
initiatives including in most institutions a Master’s degree in 
clinical and translational research and two types of formal 
clinical research training awards, the TL1 and KL2. Th ere were 
485 scholars and 445 trainees reported in 2010. TL1 awards 
off er medical, predoctoral, and postdoctoral student trainees an 
introduction to clinical and translational research. In the KL2 
program, scholars who already have MD, PhD, or other health-
related degrees and who are joining the faculty of academic 
institutions may pursue additional training expertise and obtain 
either a master’s or doctoral level degree pertinent to clinical and 
translational research. Th e didactic elements of these programs 
are complemented with full-time laboratory or clinically based 
research. Th e consortium has also developed and dispersed a 
comprehensive set of 14 core competencies ( Figure 3 ) needed 
to initiate a successful career in C&T research. 10 In addition, a 
Virtual University portal houses educational content on courses, 
competencies, and best practices shared by the consortium and 
open to the research training community at large. 11 Training in 
mentoring of trainees and junior scientists, and dissemination 
of best practices for mentoring are incorporated into CTSA 
programs. Each CTSA institution off ers pilot project research 
funding to young investigators on a competitive basis enabling 
trainees and scholars the opportunity to generate preliminary 
data. 
 Networked Assets and Shared Tools 
 Dedicated clinical research facilities 
 Th e strong emphasis being placed by NCATS to catalyze the 
development of novel diagnostic, therapeutic, or preventative 
approaches will bring with it a requirement for specialized 
infrastructure and expertise to conduct complex studies (“fi rst-
in-humans” studies) under two contexts. First, the successful 
development of novel therapeutic approaches at some point 
requires fi rst-in-human testing. Th is step in translation requires 
specialized, controlled settings that have the capabilities to 
generate high-quality research data and assure participant safety 
in the event of adverse events. Second, translation of important 
mechanistic insights from preclinical models to validation in 
humans oft en requires complex testing of the type that cannot be 
 Figure 2.  Pilot programs are supported at every CTSA; these programs stimulate essential, small-scale scientifi c investigation. 
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done safely and with high quality in standard clinical facilities, and 
requires specialized facilities and expertise. Th e nation’s clinical 
research centers (CRCs, funded by NCATS and housed within 
the CTSAs) have been designed with these two components 
in mind, and provide nursing care, space, and dedicated 
facilities that support the conduct of inpatient, outpatient, and 
community-based research. Th e 625+ inpatient beds and the 800+ 
outpatient facilities available throughout the CTSAs represent 
a virtual research hospital, geographically dispersed to serve 
patients where they live. Th e outpatient facilities are inherently 
convenient research sites in close proximity to large, diverse 
patient populations. In addition, a coordinated core laboratory 
system is oft en available, providing centralized, research-grade 
blood and urine testing, radiological studies, genomic, proteomic, 
and metabolomic studies, and many other off erings. Nationally, 
CRCs conduct a vibrant portfolio of advanced, mechanistic 
patient-oriented research and a full range of human research 
studies encompassing multiple therapeutic modalities at every 
stage of the process of product development, from new target 
identifi cation to discovery through phase 1 studies, and beyond. 
Pharmacokinetic/pharmacodynamic (PK/PD) studies which 
require precise timing of drug administration, blood draws and 
processing, and constant monitoring for the highest standard of 
safety, are a particular strength; many could not be conducted 
without the CRC, including studies sponsored by categorical 
NIH I/Cs. CRCs are also positioned to aid in drug repurposing, 
a stated priority of NCATS. 
 Rare diseases translational research 
 Th e CTSA facilities are especially critical to research aimed at fi nding 
the cause and cure of rare diseases since by their very nature rare 
disease investigations oft en require multiinstitutional participation 
in order to recruit adequately. Although we estimate that there are 
about 7,000 individual rare diseases, the number recognized grows 
by 1–2 per week. 12 Approximately, 30 million Americans have a 
rare disease. Elucidation of the genetic bases of these diseases can 
provide targets for drug discovery, which may help the patient 
with a rare disease, but also informs the discovery process for more 
common diseases, elucidating elements of the biological networks 
disrupted in these conditions. All the capabilities of the CTSAs, 
from bench to bedside, from genomics to drug discovery, and from 
phase 1 to therapeutic trials, can be readily applied to understanding 
the pathogenesis of rare diseases 
and developing diagnostic and 
therapeutic approaches to their 
management. Furthermore, given 
the scope of the CTSA consortium, 
the network renders feasible the 
conduct of defi nitive clinical trials, 
even in “rare” disorders such as 
those in the Rare Disease Clinical 
Research Consortia of the Office 
of Rare Diseases Research. The 
CTSAs currently support most of 
the 60 clinical trials of the 18 Rare 
Disease Clinical Research Consortia 
of the Office of Rare Diseases 
Research aimed at elucidating the 
pathophysiology and treatment of 
rare diseases. 
 Human assets 
 Dr. Francis Collins has noted that opportunities abound to leverage 
adaptive trial designs. 13 Yet, complex sequential or adaptive 
clinical trial designs require specialized statistical knowledge. It 
is particularly diffi  cult when using novel experimental designs 
to conduct simulation work necessary to develop an optimal 
design to address a specifi c experimental hypothesis, the relevant 
experience will therefore never reside in one place for every study 
type. However, collective expertise exists throughout the CTSA 
consortium. Th e Biostatistics Epidemiology and Research Design 
committee forms a unique network of biostatistical experts with 
expertise in the design of complex experiments, fl exible adaptive 
design, and nonstandard analytic approaches tailored to specifi c 
translational and clinical technologies. Th ese individuals develop 
new methods and apply them to real studies, including adaptations 
to existing methods, such as extensions to the sequential parallel 
comparison design (SPCD) 14 intended to reduce the problem 
of the strong placebo response while minimizing overall study 
time and sample size. Many other human assets (Investigational 
New Drug experts, Data Safety Monitoring Boards, etc.) exist 
throughout the consortium. 
 Capturing and managing data 
 Data management tools for the support of diverse clinical trials 
have been adopted or created throughout the CTSA consortium, 
including REDCap, OnCore CRM soft ware, and Velos eResearch. 
Th e development and implementation of electronic tools to enable 
interinstitutional data exchange and collaborations between 
investigators at multiple institutions has supported collaborative 
research across the CTSA consortium. For example, REDCap is 
an easy-to-use,  freely available tool for clinical study management 
and data capture that has been adopted at over 300 academic and 
non-profi t institutions and is now serving 39,000 users. Th e entire 
REDCap program has been translated into multiple languages, 
enabling its use worldwide. 15 
 Collaboration tools to enable multisite translational science 
 Finding experts, specialized equipment or other resources within 
even  a single academic medical center can be a formidable task. 
Rapid identifi cation of scientifi c experts can inform identifi cation of 
collaborators, assembling of scientifi c teams, and matching mentors 
with junior faculty members and trainees. Many CTSA institutions 
 Figure 3.  The consortium has developed and dispersed a comprehensive set of 14 core competencies needed to initiate a 
successful career in C&T research (left) with an example of the subtopics for one competency provided (right). 
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have developed and/or adopted systems related to profi ling faculty 
and staff  members. Notable examples include: (1) VIVO, an open 
source semantic Web application used by an international network 
of institutions to collect and share information about researcher 
interests, expertise, publications, and grants 16 ; (2) Profi les Research 
Networking soft ware, a similar platform for collecting and storing 
researcher profi le information with a rich network analysis and 
data visualization user interface 17 ; and (3) SciVal Experts, a 
commercial expertise profi ling and research networking tool 
featuring automated extraction and packaging of data from NIH 
Reporter and Scopus. 18 Th e Direct2Experts project was launched in 
2011 as a proof-of-concept federation project, compiling researcher 
profi le data from 28 universities for use in a single soft ware user 
interface. 19 Similarly, the biostatistics committee’s CTSpedia.
org wiki is a research methodology and research ethics resource 
containing a wealth of material including how to do reproducible 
research, statistical graphics, analysis, and design. 20 
 The Ability to Conduct Real-World Investigation 
 Under its authorizing statute, NCATS may develop and provide 
infrastructure and resources for all phases of clinical trials 
research and provide direct support for clinical trials through the 
end of phase IIa. CTSAs have made signifi cant contributions to 
biomedical research by providing the support and infrastructure 
for clinical studies from early stage phase I toxicology studies to 
community-based and comparative eff ectiveness research (CER). 
Th is infrastructure support has accelerated the translation of 
diagnostic, therapeutic, and prognostic discoveries to clinical 
application. Community engagement (CE) and comparative 
eff ectiveness provide essential insight to establishing the true 
overall impact of a new therapy under real-world conditions; that 
is, aft er drugs have received marketing approval. 
 Comparative eff ectiveness research 
 CER tests not only real-world effi  cacy of new versus established 
treatment but also the relative utility and cost-effectiveness 
of competing preventive, diagnostic, therapeutic, surgical, 
and behavioral strategies in use. CTSAs have established the 
infrastructure and personnel (such as health services researchers, 
implementation scientists, and epidemiologists, within and outside 
our medical schools) to facilitate these evaluations. Data show that 
people—and that is  all people, of any race, gender, socioeconomic 
level, or insurance status—receive only half of recommended care. 21 
Similarly, patients only receive approximately 60% of recommended 
pharmacologic care. 22 Th us, on average, a drug with 100% effi  cacy 
(of which there are very few) could only have an “applied effi  cacy” 
of 60% in a real-world setting. We recognize that actually getting 
people to take medications would not be the central mission of 
NCATS; however, given the important population health change 
that would occur with small medication adherence gains, through 
investigation we can determine the reasons for poor adherence to 
treatments and determine what infrastructure changes are needed 
to promote acceptance of new, and older, therapies. Th is is a task 
of the CTSAs. Further, the development of CER capitalizes on the 
public’s investment (via taxes and drug prices) in developing new 
therapies by increasing the likelihood of turning them into actual 
health improvements. 
 Community engagement 
 Social and environmental factors 23 impinge directly and heavily on 
the health of Americans and so we must understand community 
and social factors as determinants of health. Th e CTSAs, through 
their CE cores, have built bridges between the public and the 
increasingly complex translational research community. Th e 
community is well positioned to identify the hierarchy of unmet 
medical needs that must be addressed by research. CTSAs have 
established community research advisory boards, community 
research education programs, relationships with practice-based 
research networks (PBRNs), registries of patients and volunteers, 
and have supported the ability of community-based physicians to 
obtain and record information necessary for research that refl ects 
real-world performance on new therapies and interventions. Th e 
CTSA’s potential to use advances in informatics, and to integrate 
expertise in genomics, epigenomics, and metabolomics into such 
studies promises to give novel mechanistic insights into how 
these sociocultural variables modulate behavior and response 
to therapeutics. 
 Shared data infrastructure 
 CTSAs are developing electronic methodologies of data 
collection from diverse sources, data collation and verifi cation, 
and sharing of information, as well as newer computational and 
statistical approaches to handling large, nonuniform data sets. 
Th ese opportunities will be enhanced by the deployment of 
electronic health records to primary care practices nationwide, 
and establishment of health information exchanges to pull data 
from those practices in a secure and HIPAA compliant fashion. 
We believe a sizeable proportion of the 100 Initial Priority Topics 
for CER issued by IOM 24 would benefi t from combined EMR-
based data analyses. Author: Please provide the expanded form 
of HIPAA and IOM. What other creative and transformational 
ways can EMR data be used? We could, for example, develop 
analytical approaches for leveraging real-world data to assess drug 
safety, including the particular issue of drug combinations that are 
common in practice but rarely formally addressed in randomized 
trials. Th e advent of “meaningful use” should make shared data 
infrastructure even more appealing 25 and already there are federal 
eff orts aimed at progress in this domain, particularly in the area 
of adverse events. 26,27 Elucidation of the genetic bases of rare drug 
responses is also a key national initiative and can lead to more 
effi  cient clinical trials. 28 Th e CTSAs off er biomedical informatics, 
pharmacological and epidemiologic expertise, among other key 
disciplines, as well as a network of 60 centers incentivized to 
resolve challenges. 
 A discipline for regulatory science 
 CTSAs foster the emergence of regulatory science in academia, 29 
which is critical to the mission of NCATS and has recently 
been the subject of an IOM workshop. 30 Th e need for a strong 
workforce trained in the arena of regulatory science and 
the importance of regulatory science as an essential fi eld of 
biomedical research enterprise 31 is unambiguous. Based on 
inclusive organizational structure, the CTSAs are quite possibly 
the only national entities that contain the breadth of disciplinary 
components (over 40 listed in the IOM workshop publication) 
required to determine the impact of rules and laws governing 
FDA-regulated research. Perhaps the T1–T4 subdivision of 
translational science can be used to create a parallel subdivision 
encompassing preclinical evaluation of safety and effi  cacy, 
clinical trial design and analysis, postmarketing review of safety 
and optimal utilization, and health policies, including social 
aspects of regulatory science. 
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 Future Directions as We Move to NCATS 
 Leveraging strengths 
 A consortial approach to leveraging human and infrastructural 
assets will be enabled by the CTSA’s informatics tools that 
accommodate sharing of heterogeneous data, an array of EMRs 
as a powerful network resource for C&T studies, the innovative 
services and expertise created by CTSA 1.0, the CTSA’s capacity 
for sophisticated first-in-human studies, and our ability to 
streamline regulatory processes, enhance commercialization of 
new discoveries, build biobanks, form collaborations with offi  ces 
of technology transfer, and more. We have created new models of 
CEthat could truly accelerate the translation of research into health 
care. All of these assets present an ideal platform for development 
of therapeutics and diagnostics, primary prevention studies, 
networked clinical trials, CER, and studies of emergent public 
health needs (e.g., H1N1 infl uenza vaccine effi  cacy). Many CTSAs 
represent a microconsortium of regional institutions beyond the 
primary award site. In this manner, we have become organized 
with 60 CTSAs as nodes, with regional clusters of institutions 
around each CTSA, facilitated by a coordinating center, to provide 
a national infrastructure for CTS. 
 Working with NIH partners 
 A key feature of NCATS will be new creative, formal, transparent 
mechanisms for interaction of CTSA 2.0 with NIH I/C’s. Strong, 
practical partnerships with I/Cs will be essential if the CTSA 
is to synergize with other NCATS programs, tackle tough 
scientifi c questions and challenge areas, and address discovery 
and development in pediatric and older populations, and in 
minority communities. Th ese partnerships are being initiated now. 
Working effi  ciently  within NCATS will also be a main priority. 
For example, there is a national interest, due to inherent cost 
and time effi  ciency, in drug rescue and repurposing initiatives. 32 
Th e compounds categorized and available through the Chemical 
Genomics Center Pharmaceutical Collection 33 eff ort are likely to 
be maintained by the NCATS Division of Preclinical Innovation. 
CTSAs are in the process of complementing these initiatives 
by providing inpatient and outpatient clinical trials resources 
supported by high-quality infrastructure, advanced methods, 
accelerated IRB review processes, and readily identifi able basic 
and clinical domain expertise. Th ese resources greatly enhance the 
capability to pursue the discovery, development and application 
of novel therapeutics, devices, and diagnostics. We also hope to 
help develop collaborative eff orts with the new Cures Acceleration 
Network as it takes shape. 
 Human capital 
 Perhaps the most critical element of our mission is human 
capital. Th e integration of many diverse talents is critical to 
the successful discovery, development, and adoption of a novel 
therapeutic. Across the spectrum of this endeavor are many 
established specialties that are well represented within CTSAs and 
supported by their training programs. Th ese include traditional 
basic sciences and clinical disciplines, clinical epidemiology, and 
health services research. However, a stepchild within the “big tent” 
of clinical and translational research that spans the translational 
divide—so called T1 research. Th is catalytic endeavor not only 
lacks a name but with the erosion of clinical pharmacology as an 
academic discipline over the past 20 years a critical defi ciency 
in human capital has emerged. 34 NCATS, based on the Science 
Management Review Board report on Translational Medicine 
and Th erapeutics (TMAT), might foster the development of this 
discipline by incentivizing use of existing training systems within 
CTSAs. It might motivate the development of sustainable career 
structures in translational science in the recognition that many 
graduates would return to traditional disciplines better equipped 
to pursue this aspect of CTS within academia or move on to 
careers in the pharmaceutical, biotech and venture industries, or 
in the FDA. 35 Training and education in emerging disciplines such 
as TMAT and Regulatory Science will provide a crucial practical 
and intellectual substrate for what NCATS seeks to achieve. 
 Partnerships between public and private organizations 
 It is undisputed that innovative solutions are required to address 
the translational valley of death, the steepening patent cliff , 36 and 
the lack of therapeutic agents being approved despite increased 
industry investments. 37 During this time, the cost of this endeavor 
has risen dramatically, refl ecting primarily the increasing cost 
of failure. Indeed, the number of new drugs approved each year 
has remained roughly constant for  over 50 years. 38 Proposals to 
shake up the status quo are arising, including crowd sourcing, 39 
open access models, various public–private partnerships, 
precompetitive collaboration, 40 venture philanthropy, 41 industry 
investment (e.g., Global Centers for Th erapeutic Innovation 42 ) 
and even prizes for solving development challenges. 43 All seem 
worthwhile. Th e CTSA programs, housed within leading academic 
medical centers, are poised to take responsibility for the portions 
of the translational process that we can solve, and to take action 
when new, proven methods arise. 
 New target discovery, lead identifi cation, proof of mechanism 
studies in both animal models and in humans, and the related 
intellectual property licensing to the private sector, are critical 
steps on the path to bringing new therapies to the public. 
CTSA institutions now collaborate with their respective offi  ces 
of technology transfer and licensing. Half of CTSA sites have 
created formalized novel programs with technology accelerators, 
innovation incubators, and commercialization facilitation. Th e 
CTSA’s Intellectual Property portal is a Web-based, open access 
IP search tool that aggregates and promotes technologies from 
CTSA sites in order to stimulate collaborative research activity by 
encouraging the formation of new public–private partnerships. 44 
Similarly, the Pharmaceutical Assets Portal is a tool that provides 
academic researchers access to potential small molecules that 
may be available for repurposing within industry, 45 whereas  i2i 
connect is a consortium tool that connects academic inventors 
with device and biotechnology companies. 46 Another example is 
the Patient Impact Initiative, a collaboration between CTSA sites 
and Partnership for Cures, a nonprofi t foundation focused on 
rediscovery research. 47 Th e consortium has developed a package 
of sharable competencies for drug and device development 
focused on the ability to develop new drugs, manage the 
regulatory process, recruit collaborating investigators, design 
clinical trial protocols, prepare budgets and contracts, address 
IRB requirements, perform data safety monitoring, and execute 
business models to bring a new drug or device to market. 
 Measurement 
 An ongoing challenge of large-scale, complex organizations 
such as NCATS and the CTSA Consortium is to set in place 
metrics of success that eff ectively assess the impact of clinical 
and translational research and thereby guide biomedical science 
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and health care policies at the national level. Th e CTSAs have 
now created the infrastructure to: (1) facilitate clinical trials 
designed to test new diagnostics and therapeutics discoveries and 
(2) determine how best to bring health improvement innovations 
to the public. Now we need to measure the real-world impact of 
these new interventions. Th is is a daunting challenge; however, 
our all-encompassing pursuit is to be a network of action rather 
than soliloquy. We will make practical, noticeable progress on this 
front, including embracing any NIH-driven metrics. 48 
 Conclusion 
 To prepare for CTSA 2.0, we will complete a cataloging of resources 
from across the Consortium, including those that can be deployed 
for the discovery, development, and transfer to the private sector 
of novel therapeutics, diagnostics, and devices. We will support 
the training and career development of investigators across the 
spectrum of clinical and translational research. We will identify 
novel approaches to enhance the skills of C&T teams for developing 
new therapeutics, diagnostics, devices, preventatives, and CER 
strategies. A framework for prioritizing IT and Informatics goals 
will be established, including methods for utilization of EMRs, 
integration of such information with diverse data sets emerging 
from translational studies, and harmonization of data elements 
across sites and networks to enable reuse. Th e CTSAs will also 
develop systems to ensure eff ective communication between 
research and community networks, as well as tools to support 
new methodologies in CER. In the short time that the CTSA 
program has been fully in existence, we have become an agile 
national consortium of 60 sites dedicated to the advancement of 
translational science that is truly transdisciplinary and functions 
at multiple levels. We remain deeply committed to the mission 
of NCATS and are prepared to respond organizationally and 
scientifi cally to any initiatives arising from NCATS. 
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